Frontline Promise for Adagrasib-Pembrolizumab Combination

Area of Science:

• Oncology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
• The KRASG12C mutation is a common driver mutation in NSCLC, historically considered difficult to target.
• Targeted therapies and immune checkpoint inhibitors have revolutionized NSCLC treatment, but optimal combinations are under investigation.

Purpose of the Study:

• To evaluate the safety and efficacy of combining adagrasib with pembrolizumab in patients with newly diagnosed, KRASG12C-mutated NSCLC.
• To compare the toxicity profile of this combination with other existing treatment regimens.

Main Methods:

• Two independent clinical trials were conducted.
• Patients received adagrasib in combination with pembrolizumab.
• Outcomes assessed included overall response rate (ORR) and adverse events, particularly liver toxicity.

Main Results:

• The adagrasib plus pembrolizumab regimen demonstrated significant efficacy, with ORRs of 49% in one trial and 57% in the other.
• The combination exhibited a favorable safety profile, notably showing lower levels of liver toxicity compared to other checkpoint inhibitor and targeted therapy combinations.

Conclusions:

• Adagrasib plus pembrolizumab represents a safe and effective treatment option for patients with newly diagnosed KRASG12C-mutated NSCLC.
• This combination offers a promising therapeutic strategy with a manageable toxicity profile, potentially improving outcomes for this patient population.